State Street Corporation 13D and 13G filings for Viking Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-10-18 12:26 pm Sale | 2024-09-30 | 13G | Viking Therapeutics, Inc. VKTX | STATE STREET CORP STT | 4,666,157 4.200% | -1,066,833 (-18.61%) | Filing |
| 2024-01-24 1:24 pm Purchase | 2023-12-31 | 13G | Viking Therapeutics, Inc. VKTX | STATE STREET CORP STT | 5,732,990 5.730% | 5,486,148 (+2222.53%) | Filing |
| 2023-02-03 3:36 pm Sale | 2022-12-31 | 13G | Viking Therapeutics, Inc. VKTX | STATE STREET CORP STT | 246,842 0.320% | -3,878,725 (-94.02%) | Filing |
| 2022-02-11 9:23 pm Sale | 2021-12-31 | 13G | Viking Therapeutics, Inc. VKTX | STATE STREET CORP STT | 4,125,567 5.270% | -946,989 (-18.67%) | Filing |
| 2021-02-11 4:17 pm Purchase | 2020-12-31 | 13G | Viking Therapeutics, Inc. VKTX | STATE STREET CORP STT | 5,072,556 6.950% | 1,462,294 (+40.50%) | Filing |